Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12708363 | 0.89 | AXL (0.54) | HSD17B10TYK2JAK1INSRAXL | |
| SCHEMBL1167907 | 0.88 | TYK2 (0.49) | HSD17B10TYK2JAK1 | |
| SCHEMBL1168022 | 0.84 | TYK2 (0.51) | TYK2JAK1 | |
| SCHEMBL1167782 | 0.82 | JAK2 (0.58) | MAPK1TYK2JAK1CDK1 | |
| SCHEMBL1167615 | 0.82 | SYK (0.51) | LMNATYK2JAK1PRMT5 | |
| SCHEMBL1167301 | 0.81 | KMT2A (0.57) | TYK2JAK1CDK1CYP2C9CYP2C19 | |
| SCHEMBL12881252 | 0.81 | TYK2 (0.47) | MAPK1LMNATYK2JAK1CDK2 | |
| SCHEMBL1169249 | 0.81 | AXL (0.59) | TYK2JAK1INSRAXLCDK1 | |
| SCHEMBL1167877 | 0.80 | SMN1; SMN2 (0.48) | LMNATYK2JAK1CYP2C19ALDH1A1 | |
| SCHEMBL1167679 | 0.80 | TYK2 (0.54) | TYK2JAK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922310-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | claimed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1922310-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | HSD17B10 3572/4885MAPK1 855/4885HBB 4155/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | HSD17B10 4182/4885MAPK1 511/4885HBB 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.